Novel proteomic technologies that are so robust and powerful that they can be used in every biological laboratory and in every clinic are expected as results of the currently starting research consortium MSmed. The European Commission is co-funding the project with 3.7 Million Euros for four years starting December 1, 2015 within the research line “Future and Emerging Technologies” under the Horizon 2020 Programme. MSmed will automate workflows in mass spectrometric analysis for proteomics research to prepare them for high-throughput clinical application.
Proteins are the major functional actors within cells and exert most of the cells’ functions. Over the past decade the analysis of the protein inventory of cells and tissues, the „proteome“, has made tremendous progress showing definite promise of mass spectrometry technology in the life sciences.
To date proteome analysis is still a specialist technology and has not reached the robustness and availability for large-scale biomedical and clinical applications. In that respect it clearly lags behind genomic technologies that are, however, not applicable to protein based questions.
The MSmed project was initiated to tackle this issue. The vision of project coordinator Matthias Mann is “…to introduce proteome analysis by mass spectrometry as automated routine tool into the clinics”. Complementing current genetic methods with direct proteome analysis would allow measuring actual medical parameters as reflected in the patient’s proteome rather than solely genetic disposition.
Such a paradigm changing approach could transform personalized medicine, revolutionizing medical diagnosis and the assessment of efficacy of medical intervention on an individual basis.
To bring this vision into reality, a team was built around leaders in the proteomics field with a history of successful collaboration. They will bring in a broad range of experiences and expertise to master the various challenges lying ahead. These challenges include the development of novel instrumentation with drastically increased performance, the automation of sample preparation and analysis, the adaptation of analysis protocols to the characteristics of clinical samples, and the development of comprehensive software for extensive in-depth analysis of the large amounts of data obtained.
When successful, MSmed will establish mass spectrometry based proteomics in systems medicine, making all workflows and mass spectrometry platforms available to the community. These workflows will be used as the basis of myriad applications in biomedicine, even in the clinic. This in turn will lead to a new eco-system around improved diagnosis, elucidations of disease mechanisms and drug action.
The MSmed team
The coordinating Mann group (Novo Nordisk Foundation Center for Protein Research, University of Copenhagen and Max Planck Institute of Biochemistry, Martinsried), the Olsen group (Novo Nordisk Foundation Center for Protein Research, University of Copenhagen) , the Cox group (Max Planck Institute of Biochemistry, Martinsried), the Heck group (Utrecht University) and Makarov from the industrial partner Thermo Fisher Scientific, are all leaders in the field and have a longstanding collaboration concerning the improvement of instrumentation in mass spectrometry, with the aim to make it accessible to all researchers. One example is the earlier EU-funded project PROSPECTS, which was also coordinated by Matthias Mann, where Mann, Olsen, Cox and Makarov jointly invented novel technology for in depth quantitative proteomics and the EU-funded project PRIME-XS, coordinated by Albert Heck, wherein amongst others Mann and Olsen participated and jointly provided access to their facilities to researchers in Europe and performed joint research projects.
The coordinating center in Copenhagen brings in expertise in clinical approaches and a network of clinical collaborators. The Heck group (University Utrecht) is a key partner in technology development for novel identification methods to be used in the analysis of modified proteins. The Cox group (Max Planck Institute of Biochemistry, Martinsried) complements the lab expertise with high-end bioinformatics. Together with the Mann group they have developed the most successful and industry standard MaxQuant platform for proteomics research worldwide. Makarov, being the inventor of the leading mass analyser and research director at Thermo Fisher complements the team, and has long standing relationship with all the academic partners. These earlier achievements lend credibility to the future success of the MSmed project.
Dr. Anne Katrin Werenskiold
Max-Planck-Institut für Biochemie
Am Klopferspitz 18
Tel. +49 89 8578-2601
Dr. Christiane Menzfeld
Max Planck Institute of Biochemistry
Am Klopferspitz 18
Tel. +49 89 8578-2824
http://www.biochem.mpg.de - homepage Max Planck Institute of Biochemistry
Dr. Christiane Menzfeld | Max-Planck-Institut für Biochemie
CRTD receives 1.56 Mill. Euro BMBF-funding for retinal disease research
24.05.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
BMBF funds translational project to improve radiotherapy
10.05.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
29.05.2017 | Earth Sciences
29.05.2017 | Life Sciences
29.05.2017 | Physics and Astronomy